Prosecution Insights
Last updated: May 29, 2026

Targimmune Therapeutics AG

3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready

Portfolio Summary

3
Total Pending OAs
3
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

2
Overdue
0
Due this week
1
Due this month
0
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (2)Due ≤ 30 days (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (33%)
0
Medium (0%)
0
Easy (0%)
2
Unknown (67%)

Rejection Statute Mix

BucketCases
§101 only1 (33%)
No statute on record2 (67%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

3
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

30 h
Manual time on pending OAs
6 h
Time saved (low, 20%)
10 h
Time saved (mid, 35%)
0.3 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
LIPPOLIS, ALEXANDRA ROSE 1 36.4% +70.1%
HUDSON, AMY ROSE 1 75.1% +11.4%
ZARA, JANE J 1 70.8% +15.9%

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18316828 CASTRATION RESISTANT PROSTATE CANCER LIPPOLIS, ALEXANDRA ROSE 31d overdue

Interview Candidates (3)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.

App #TitleExaminerDue in
18316828 CASTRATION RESISTANT PROSTATE CANCER LIPPOLIS, ALEXANDRA ROSE 31d overdue
17653221 METHOD OF TREATING CANCER ZARA, JANE J 29d overdue
18247961 IMMUNOTHERAPY FOR THE TREATMENT OF CANCER HUDSON, AMY ROSE 23d

Top Art Units

Art UnitApps
1637 2
1636 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18316828 CASTRATION RESISTANT PROSTATE CANCER LIPPOLIS, ALEXANDRA ROSE 1637 §101 Non-Final OA 31d overdue Pending May 12, 2023
18247961 IMMUNOTHERAPY FOR THE TREATMENT OF CANCER HUDSON, AMY ROSE 1636 Other Non-Final OA 23d Pending Apr 05, 2023
17653221 METHOD OF TREATING CANCER ZARA, JANE J 1637 Other Non-Final OA 29d overdue Pending Mar 02, 2022

Managing Targimmune Therapeutics AG's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month